Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Cellectar Biosciences, Inc. (CLRB) had Consolidated Net Income/Loss of $-6.60M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-6.60M |
|
-- |
|
-- |
|
$6.40M |
|
$-6.40M |
|
$-0.20M |
|
$-6.60M |
|
$-6.60M |
|
$-6.60M |
|
$-6.60M |
|
|
Consolidated Net Income/Loss |
$-6.60M |
$-6.60M |
|
$-6.40M |
|
$-6.34M |
|
46.08M |
|
46.08M |
|
$-0.14 |
|
$-0.14 |
|
| Balance Sheet Financials | |
$14.89M |
|
$0.70M |
|
$1.15M |
|
$16.04M |
|
$6.02M |
|
-- |
|
$1.77M |
|
$7.79M |
|
$7.73M |
|
$8.25M |
|
$8.25M |
|
46.08M |
|
| Cash Flow Statement Financials | |
$-9.38M |
|
-- |
|
$0.00M |
|
$23.29M |
|
$13.91M |
|
$-9.38M |
|
$0.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.47 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.38M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-85.40% |
|
-80.02% |
|
-41.17% |
|
-80.02% |
|
$0.18 |
|
$-0.20 |
|
$-0.20 |
|